

XENTION PHARMA LIMITED

FINANCIAL STATEMENTS
INFORMATION FOR FILING WITH THE REGISTRAR
FOR THE YEAR ENDED 31 OCTOBER 2017

WEDNESDAY



A77JD8EI

A11

06/06/2018

#122

COMPANIES HOUSE

XENTION PHARMA LIMITED
REGISTERED NUMBER: 07376729

BALANCE SHEET
AS AT 31 OCTOBER 2017


	Note	2017 £	2016 £
FIXED ASSETS			
Investments	4	324,367	324,367
		<u>324,367</u>	<u>324,367</u>
CURRENT ASSETS			
Debtors: amounts falling due within one year	5	-	10,107
Cash at bank and in hand		8,499	328,975
		<u>8,499</u>	<u>339,082</u>
Creditors: amounts falling due within one year	6	(4,805)	(5,292)
NET CURRENT ASSETS		<u>3,694</u>	<u>333,790</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>328,061</u>	<u>658,157</u>
NET ASSETS		<u><u>328,061</u></u>	<u><u>658,157</u></u>
CAPITAL AND RESERVES			
Called up share capital	7	231,161	226,586
Share premium account		25	7
Profit and loss account		96,875	431,564
		<u>328,061</u>	<u>658,157</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by:


Dr K McCullagh
Director

Date: 24/5/18
The notes on pages 2 to 4 form part of these financial statements.

XENTION PHARMA LIMITED

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OCTOBER 2017

1. GENERAL INFORMATION

Xention Pharma Limited is a private company limited by shares and incorporated in England and Wales. The registered office is 38 High Street, Newmarket, CB8 8LB.

The functional and presentational currency is GBP.

2. ACCOUNTING POLICIES

2.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

2.2 VALUATION OF INVESTMENTS

Investments in subsidiaries are measured at cost less accumulated impairment.

2.3 DEBTORS

Short term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

2.4 CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

2.5 CREDITORS

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

2.6 DIVIDENDS

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting. Dividends on shares recognised as liabilities are recognised as expenses and classified within interest payable.

3. EMPLOYEES

The average monthly number of employees, including directors, during the year was 0 (2016 - 0).

XENTION PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2017**

4. FIXED ASSET INVESTMENTS

	Investments in subsidiary companies £
COST OR VALUATION	
At 1 November 2016	324,367
At 31 October 2017	<u>324,367</u>

5. DEBTORS

	2017 £	2016 £
Other debtors	-	9,065
Prepayments and accrued income	-	1,042
	<u>-</u>	<u>10,107</u>

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2017 £	2016 £
Trade creditors	-	1,292
Amounts owed to group undertakings	181	-
Other creditors	124	-
Accruals and deferred income	4,500	4,000
	<u>4,805</u>	<u>5,292</u>

XENTION PHARMA LIMITED

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2017**

7. SHARE CAPITAL

	2017 £	2016 £
ALLOTTED, CALLED UP AND FULLY PAID		
6,639,508 (2016 - 5,724,523) Ordinary shares of £0.005 each	33,198	28,623
7,902,435 A Ordinary shares of £0.005 each	39,512	39,512
10,672,331 B Preferred shares of £0.005 each	53,362	53,362
5,400,610 C Preferred shares of £0.005 each	27,003	27,003
14,217,145 D Preferred shares of £0.005 each	71,086	71,086
1,400,000 C Ordinary shares of £0.01 each	7,000	7,000
	<hr/> 231,161 <hr/>	<hr/> 226,586 <hr/>

During the year 914,985 Ordinary shares were issued.

8. FIRST TIME ADOPTION OF FRS 102

The policies applied under the entity's previous accounting framework are not materially different to FRS 102 and have not impacted on equity or profit or loss.

9. AUDITORS' INFORMATION

The auditors' report on the financial statements for the year ended 31 October 2017 was unqualified.

The audit report was signed on 31 May 2018 by James Burrett (Senior Statutory Auditor) on behalf of Peters Elworthy & Moore.